NCT05267327: A Prospective Post-Marketing Observational Safety Study of Verzenio (Abemaciclib) Among Breast Cancer Patients in China Verzenio (Abemaciclib) Among Breast

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting

Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 

Comments are closed.

Up ↑